Lates News
Every AI Express, Huaxun Securities released a research report on August 14, giving a buy rating to Zhongsheng Pharmaceutical (002317.SZ). The rating reasons mainly include: 1) Traditional Chinese medicine as the foundation, the stable operation of the Chinese patent medicine business provides a solid foundation for the company's development; 2) Leading innovation, the listing of the innovative drug Angolateline for the treatment of H1N1 influenza, future market space can be expected; 3) In research, the data of the long-acting GLP-1 drug RAY1225 injection is impressive, and overseas equity authorization will continue to be monitored. (Daily Economic News)
Latest
6 m ago